Back to search results

HoLEP Before Radiation for Prostate Cancer and Urinary Symptoms

This study is looking at whether a surgical procedure called Holmium Laser Enucleation of Prostate (HoLEP) can help men who have both prostate cancer and bothersome lower urinary tract symptoms (LUTS). HoLEP uses a laser to remove prostate tissue that is causing urinary problems. Researchers want to see if having HoLEP before radiation therapy for prostate cancer can improve your quality of life. You may be able to join if you are 18 or older, have bothersome LUTS (like a high AUA Symptom Score or needing a catheter), and have been diagnosed with prostate cancer. The study will measure how your quality of life changes one year and five years after the procedure. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be checked one year and five years after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03802851

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

Recruiting
NAAges 18+InterventionalTreatment
University of Kansas Medical Center
~30 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Holmium Laser Enucleation of Prostate (HoLEP)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in Quality of Life - One Year Post Operatively
Measured over Quality of life will be assessed one year post-operatively
+1 more outcome measured

Conditions

Prostate Cancer
Lower Urinary Tract Symptoms

Explore related trials

Lower Urinary Tract SymptomsProstate Carcinoma

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Bristol Whiles, MD · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Jane Ledesma, BS
[email protected]
(913) 588-8721
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must be 18 years of age or older
Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and/or as defined by a post-void residual of greater than or equal to 350mL and/or as defined by catheter dependence
Patients must be diagnosed with prostate cancer by pathological tissue analysis
Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer

Exclusion

Patients who are under 18 years of age are not eligible
Patients who have a diagnosis of bladder cancer are not eligible.
Patients with prior treatment for prostate cancer are not eligible.
Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible.
Patients with known metastatic prostate cancer are ineligible
Patients who are enrolled in other surgical or international trials at the time of this study are not eligible

What this trial measures

  • Improvement in Quality of Life - One Year Post OperativelyQuality of life will be assessed one year post-operatively

    The primary object is to determine if holmium laser enucleation of the prostate (HoLEP) improves the quality of life in patients with concurrent prostate cancer who may undergo radiation therapy as well. Quality of life will be assessed using the Expanded Prostate Cancer Index Composite (EPIC) 26. This instrument evaluates patient function and bother after prostate cancer treatment using 26 items and scored on a 0-100 scale, with higher scores indicating a better health related quality of life.

  • Improvement in Quality of Life - Five Years Post OperativelyQuality of life will be assessed five years post-operatively

    The primary object is to determine if holmium laser enucleation of the prostate (HoLEP) improves the quality of life in patients with concurrent prostate cancer who may undergo radiation therapy as well. Quality of life will be assessed using the Expanded Prostate Cancer Index Composite (EPIC) 26. This instrument evaluates patient function and bother after prostate cancer treatment using 26 items and scored on a 0-100 scale, with higher scores indicating a better health related quality of life.